A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NCT06326411)
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Who can join: Review the eligibility criteria below.
Location: UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- UCLA Hematology/Oncology — Westwood, Los Angeles, California
- Sarah Cannon Research Institute at Health ONE — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Moffitt Cancer Center — Tampa, Florida
- Roswell Park — Buffalo, New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Columbia University Medical Center — New York, New York
- Memorial Slone Kettering Cancer Center — New York, New York
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- NEXT Oncology - Austin — Austin, Texas
- NEXT Oncology - Dallas — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- START Moutain Region — West Valley City, Utah
- NEXT Oncology - Virginia — Fairfax, Virginia
- The Kinghorn Cancer Center, St. Vincent's Health Network — Darlinghurst, New South Wales
- Scientia Clinical Research, Ltd — Randwick, New South Wales
- Gallipoli Medical Research Centre- Greenslopes Private Hospital — Greenslopes, Queensland
- Southern Oncology Research Unit — Adelaide, South Australia
- Cabrini Health Limited — Malvern, Victoria
- Cabrini Hospital — Malvern, Victoria
📞 Contact the Study Coordinator
Phone: (617) 468-4292
Email: info@nestedtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Oncology
- Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation — Miami, Florida
- Ask Questions About Clinical Trials — Bay City, Michigan
- xPedite: A Study to Expedite DIPG and DMG Research — Los Altos, California
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study — Pittsburgh, Pennsylvania
- STEP2 vs. Routine Early Palliative Care: Randomized Noninferiority Trial — Toronto, Ontario
Explore by condition: All Oncology clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.